Clinical symptoms in patients with myositis - An acquired metabolic myopathy?

Current Opinion in Rheumatology

Volumn 15, Issue 6, 2003, Pages 675-678

  Lundberg, Ingrid E ^a  

^a KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

ADENOSINE TRIPHOSPHATE; ANTIINFLAMMATORY AGENT; CELL ADHESION MOLECULE; CHEMOKINE; CREATINE PHOSPHATE; CYTOKINE; ENDOSTATIN; GAMMA INTERFERON; IMMUNOSUPPRESSIVE AGENT; INTERCELLULAR ADHESION MOLECULE 1; INTERFERON; INTERLEUKIN 1ALPHA; INTERLEUKIN 1BETA; THROMBOSPONDIN; TRANSFORMING GROWTH FACTOR; TROPONIN I; VASCULOTROPIN;

ANGIOGENESIS; CAPILLARY; CELL INCLUSION; CELL INFILTRATION; DERMATOMYOSITIS; EDITORIAL; ENDOTHELIUM CELL; EXERCISE; FATIGUE; HISTOPATHOLOGY; HUMAN; HYPOXEMIA; METABOLIC DISORDER; METABOLIC MYOPATHY; MICROVASCULATURE; MITOCHONDRION; MUSCLE METABOLISM; MUSCLE STRENGTH; MUSCLE WEAKNESS; MYOPATHY; MYOSITIS; PATIENT; PHENOTYPE; POLYMYOSITIS; PRIORITY JOURNAL; PROTEIN EXPRESSION; SYMPTOMATOLOGY; VASODILATATION;

ANOXIA; DIAGNOSIS, DIFFERENTIAL; FEMALE; HUMANS; MALE; MUSCLE WEAKNESS; MUSCLE, SKELETAL; MUSCULAR DISEASES; MYOSITIS; NEUROMUSCULAR DISEASES; PROGNOSIS; RISK FACTORS;

EID: 0742287036     PISSN: 10408711     EISSN: None     Source Type: Journal    
DOI: 10.1097/00002281-200311000-00001     Document Type: Editorial

References (26)

1. Engel AG, Arahata K: Mononuclear cells in myopathies: quantitation of functionally distinct subsets, recognition of antigen-specific cell-mediated cytotoxicity in some diseases, and implications for the pathogenesis of the different inflammatory myopathies. Hum Pathol 1986, 17:704-721.
2. Nyberg P, Wikman AL, Nennesmo I, et al.: Increased expression of interleukin 1 alpha and MHC class I in muscle tissue of patients with chronic, inactive polymyositis and dermatomyositis. J Rheumatol 2002, 27:940-948.
3. Plotz PH, Dalakas M, Leff RL, et al.: Current concepts in the idiopathic inflammatory myopathies: polymyositis, dermatomyositis, and related disorders. Ann Intern Med 1989, 111:143-157.
4. Englund P, Nennesmo I, Klareskog L, et al.: Interleukin-1 α expression in capillaries and major histocompatibility complex class I expression in type II muscle fibers from polymyositis and dermatomyositis patients. Arthritis Rheum 2002, 46:1044-1055.
5. Joffe MM, Love LA, Leff RL, et al.: Drug therapy of the idiopathic inflammatory myopathies: predictors of response to prednisone, azathioprine and methotrexate and a comparison of their efficacy. Am J Med 1993, 94:379-387.
6. Bodamyali T, Stevens CR, Billingham ME, et al.: Influence of hypoxia in inflammatory synovitis. Ann Rheum Dis 1998, 57:703-710.
7. Emslie-Smith AM, Engel AG: Microvascular changes in early and advanced dermatomyositis: a quantitative study. Ann Neurol 1990, 27:343-356.
8. Newman ED, Kurland RJ: P-31 magnetic resonance spectroscopy in polymyositis and dermatomyositis. Arthritis Rheum 1992, 2:199-203.
9. Park JH, Vital TL, Ryder NM, et al.: Magnetic resonance imaging and P-31 magnetic resonance spectroscopy provide unique quantitative data useful in the longitudinal management of patients with dermatomyositis. Arthritis Rheum 1994, 37:736-746.
10. Park JH, Vital TL, Ryder NM, et al.: Use of magnetic resonance imaging and P-31 magnetic resonance spectroscopy to detect and quantify muscle dysfunction in the amyopathic and myopathic variants of dermatomyositis. Arthritis Rheum 1995, 38:68-77.
11. De Bleecker JL, Engel AG: Expression of cell adhesion molecules in inflammatory myopathies and Duchenne dystrophy. J Neuropathol Exp Neurol 1994, 53:369-376.
12. Lundberg I, Ulfgren AK, Nyberg P, et al.: Cytokine production in muscle tissue of patients with idiopathic inflammatory myopathies. Arthritis Rheum 1997, 40:865-874.
13. Lundberg I, Kratz AK, Alexanderson H, et al.: Decreased expression of interleukin-1 alpha, interleukin-1 beta, and cell adhesion molecules in muscle tissue following corticosteroid treatment in patients with polymyositis and dermatomyositis. Arthritis Rheum 2000, 43:336-348.
14. Chariot P, Ruet E, Authier FJ, et al.: Cytochrome c oxidase deficiencies in the muscle of patients with inflammatory myopathies. Acta Neuropathol 1996, 91:530-536.
15. Niinikoski J, Paljarvi L, Laato M, et al.: Muscle hypoxia in myositis. J Neurol Neurosurg Psychiatry 1986, 49:1455.
16. Ferrara N, Gerber H-P, LeCouter J: The biology of VEGF and its receptors. Nat Med 2003, 9:669-676.
17. Grundtman, CM, Dastmalchi M, Lundberg I, et al.: Vascular endothelium growth factor (VEGF) expression changes with corticosteroid treatment in muscle tissue in patients with poly- and dermatomyositis [abstract SAT 0040]. Ann Rheum Dis 2002, 6(suppl).
18. Tham E, Wang J, Piehl F, et al.: Upregulation of VEGF-A without angiogenesis in a mouse model of dilated cardiomyopathy caused by mitochondrial dysfunction. J Histochem Cytochem 2002, 50:935-944.
19. Gustafsson T, Knutsson A, Puntschart A, et al.: Increased expression of vascular endothelial growth factor in human skeletal muscle in response to short-term one-legged exercise training. Eur J Physiol 2002, 444:752-759.
20. Hoppeler H, Flück M: Normal mammalian skeletal muscle and its phenotypic plasticity. J Exp Biol 2002, 205:2143-2152.
21. Olfert IM, Breen EC, Mathieu-Costello O, et al.: Chronic hypoxia attenuates resting and exercise-induced VEGF, flt-1, and flk-1 mRNA levels in skeletal muscle. J Appl Physiol 2001, 90:1532-1538.
22. Li YP, Reid MB: Effect of tumor necrosis factor-α on skeletal muscle metabolism. Curr Opin Rheumatol 2001, 13:483-487.
23. Lundberg IE, Dastmalchi M: Possible pathogenic mechanisms in inflammatory myopathies. Rheum Dis Clin North Am 2002, 28:799-822.
24. Wortmann RL: Metabolic diseases of muscle. In Diseases of Skeletal Muscle. Edited by Wortmann RL. Philadelphia: Lippincott Williams & Wilkins; 2000:157-187.
25. Wiesinger GF, Quittan M, Aringer M, et al.: Improvement of physical fitness and muscle strength in polymyositis/dermatomyositis patients by a training programme. Br J Rheumatol 1998, 37:196-200.
26. Alexanderson H, Stenström CH, Lundberg I: Safety of a home exercise programme in patients with polymyositis and dermatomyositis: a pilot study. Rheumatology 1999, 38:608-611.